Golden State Equity Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Golden State Equity Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.9K	Sell	151 -175	-54%	-$23.7K	0.06%	167
2026 Q1	$41.7K	Buy	+326	New	+$40.7K	﹤0.01%	925
2024 Q4	–	Sell	-25	Closed	-$2.47K	–	898
2024 Q3	$2.47K	Buy	+25	New	+$2.46K	﹤0.01%	792
2023 Q4	$521K	Buy	5,835 +59	+1%	+$4.38K	0.13%	182
2023 Q3	$422K	Buy	5,776 +736	+15%	+$58.8K	0.12%	188
2023 Q2	$419K	Buy	5,040 +1,156	+30%	+$96.7K	0.12%	206
2023 Q1	$296K	Buy	+3,884	New	+$322K	0.16%	150

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Golden State Equity Partners's XBI Position: Q2 2026 in Review

Golden State Equity Partners reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 54% in Q2 2026, selling an estimated $23.7K and leaving 151 shares worth $23.9K. The position accounts for 0.06% of the portfolio, ranked #167.

Golden State Equity Partners first reported a position in XBI in Q1 2023 and has held it in 7 quarters since. The position peaked at $521K in Q4 2023. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Golden State Equity Partners held 151 shares of State Street SPDR S&P Biotech ETF worth $23.9K as of Q2 2026.
Golden State Equity Partners sold 175 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $23.7K.
State Street SPDR S&P Biotech ETF made up 0.06% of Golden State Equity Partners's portfolio in Q2 2026, its #167 holding.
Golden State Equity Partners first reported a position in State Street SPDR S&P Biotech ETF in Q1 2023 and has held it in 7 quarters since.
Golden State Equity Partners's State Street SPDR S&P Biotech ETF position peaked at $521K in Q4 2023.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.